FDA Clearance Tracker · P990081-S054
PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
Last checked: Nov 20, 2026Latest source record: Nov 20, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Nov 20, 2024
Approved
Time to decision
208 days
Received Apr 26, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P990081-S054
- Device name
- PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
- Applicant
- Ventana Medical Systems, Inc.
- Applicant location
- Tucson, AZ
- Received
- Apr 26, 2024
- Decided
- Nov 20, 2024
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P990081
Device type
- Device type
- SYSTEM, TEST, HER-2/NEU, IHC (MVC)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody (PATHWAY anti-HER2 (4B5) antibody) is a rabbit monoclonal antibody intended for laboratory use for the semi-quantitative detection of HER2 antigen by immunohistochemistry (IHC) in sections of formalin-fixed, paraffin-embedded breast carcinoma and biliary tract cancer (gallbladder adenocarcinoma, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma) tissue using the ultraView Universal DAB Detection Kit on a BenchMark ULTRA instrument. The IHC device is indicated for identifying patients who are eligible for treatment with the following therapies in accordance with the approved therapeutic labeling: Indication for use Status TherapyBreast carcinoma IHC 3+ or IHC 2+/ISH amplified Herceptin®Breast carcinoma IHC 3+ or IHC 2+/ISH amplified KADCYLA®Breast carcinoma IHC 1+ or IHC 2+/ISH non-amplified ENHERTU®Biliary tract cancer IHC 3+ ZIIHERA®Test results should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.This product is intended for in vitro diagnostic (IVD) use.
Source documents
Other decisions for Ventana Medical Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- VENTANA HER2 Dual ISH DNA Probe CocktailPMA supplement
P190031-S016 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer (NYQ) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.